HC Wainwright Has Optimistic View of GH Research Q1 Earnings

GH Research PLC (NASDAQ:GHRS) – Equities researchers at HC Wainwright upped their Q1 2025 earnings estimates for shares of GH Research in a research report issued to clients and investors on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.19) for the quarter, up from their prior forecast of ($0.22). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research’s Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.92) EPS and FY2028 earnings at ($0.46) EPS.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06.

A number of other research analysts have also issued reports on the stock. Cantor Fitzgerald began coverage on shares of GH Research in a report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price objective for the company. Stifel Nicolaus raised their price target on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Finally, Canaccord Genuity Group lowered their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, GH Research presently has an average rating of “Buy” and a consensus price target of $30.60.

GH Research Price Performance

Shares of NASDAQ GHRS opened at $10.55 on Friday. The company has a 50 day simple moving average of $10.73 and a 200 day simple moving average of $9.20. The firm has a market cap of $548.90 million, a PE ratio of -13.35 and a beta of 0.94. GH Research has a 1 year low of $6.00 and a 1 year high of $20.50.

Institutional Trading of GH Research

Several hedge funds have recently modified their holdings of the stock. Woodline Partners LP increased its stake in shares of GH Research by 112.0% in the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock valued at $553,000 after acquiring an additional 41,711 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of GH Research in the 4th quarter valued at $117,000. Millennium Management LLC bought a new stake in shares of GH Research in the 4th quarter valued at $145,000. BNP Paribas Financial Markets acquired a new stake in GH Research in the 4th quarter valued at $44,000. Finally, AdvisorShares Investments LLC grew its position in GH Research by 15.4% in the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after purchasing an additional 4,806 shares during the period. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).